MDM2 and cancer: In comparison, according to the GENIE database (total, 13,473 samples), MDM2 amplification has been reported in 5.5% (744 of 13,473) of diverse cancers, including liposarcoma (69.1% [47 of 68]); gallbladder, adenocarcinoma (17.5% [seven of 40]); sarcoma, not otherwise specified (25.0% [four of 16]); and urothelial carcinoma (10.7% [48 of 446]; Fig 1).